Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ487489-2,20
KB755,5756-3,26
PKN69,6469,7-4,77
Msft-4,31
Nokia3,693,7-2,65
IBM-2,28
Daimler AG39,7339,75-6,74
PFE-2,94
25.02.2020 1:37:51
Indexy online
AD Index online
select
AD Index online
 

  • 24.02.2020
Amgen Inc (AMGN.O, NASDAQ Cons)
Závěr k 24.2.2020 Změna (%) Změna (USD) Objem obchodů (ks)
217,88 -2,20 -4,91 3 048 804
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 25.02.2020
Popis společnosti
Obecné informace
Název společnostiAmgen, Inc.
TickerAMGN
Kmenové akcie:Ordinary Shares
RICAMGN.O
ISINUS0311621009
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.12.2019
Počet zaměstnanců k 31.12.2019 23 400
Akcie v oběhu k 06.02.2020 589 806 819
Počet akcionářů k 31.12.2019 5 493
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice1 Amgen Center Dr
MěstoTHOUSAND OAKS
PSČ91320-1730
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 054 471 000
Fax18054471010

Business Summary: Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Amgen, Inc. revenues decreased 2% to $23.36B. Net income decreased 7% to $7.84B. Revenues reflect US segment decrease of 5% to $16.53B, Other segment decrease of 5% to $1.16B. Net income also reflects Research and development increase of 10% to $4.12B (expense), Interest income decrease of 20% to $643M (income). Dividend per share increased from $5.28 to $5.80.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations



  • Poslední aktualizace: 25.02.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerRobert Bradway5601.01.201310.04.2007
Chief Financial Officer, Executive Vice PresidentPeter Griffith6001.01.2020
Executive Vice President of Global Commercial OperationsMurdo Gordon5203.09.201803.09.2018
Executive Vice President - Research and DevelopmentDavid Reese5626.07.201826.07.2018
Executive Vice President, OperationsEsteban Santos51
Senior Vice President, Chief Compliance OfficerCynthia Patton5722.10.201222.10.2012
Senior Vice President, General Counsel, SecretaryJonathan Graham58
Senior Vice President - Human ResourcesLori Johnston5402.11.2016
Senior Vice President - Business DevelopmentDavid Piacquad62